EA202190096A1 - Композиция, содержащая аналог соматостатина, для радиофармацевтического применения - Google Patents

Композиция, содержащая аналог соматостатина, для радиофармацевтического применения

Info

Publication number
EA202190096A1
EA202190096A1 EA202190096A EA202190096A EA202190096A1 EA 202190096 A1 EA202190096 A1 EA 202190096A1 EA 202190096 A EA202190096 A EA 202190096A EA 202190096 A EA202190096 A EA 202190096A EA 202190096 A1 EA202190096 A1 EA 202190096A1
Authority
EA
Eurasian Patent Office
Prior art keywords
somatostatin
composition containing
containing analogue
radiopharmaceutical
application
Prior art date
Application number
EA202190096A
Other languages
English (en)
Inventor
Мари Дельпорт
Забине Хофест
Йенс Кауфманн
Деннис Мевис
Анн Пети
Жоэль РИШАР
Original Assignee
Ипсен Фарма С.А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ипсен Фарма С.А.С. filed Critical Ипсен Фарма С.А.С.
Publication of EA202190096A1 publication Critical patent/EA202190096A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121Solutions, i.e. homogeneous liquid formulation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к композиции аналога соматостатина для радиофармацевтического применения, в частности для диагностического или терапевтического применения. Более конкретно, аналог соматостатина представляет собой рецептор-селективный антагонист соматостатинового пептида.
EA202190096A 2018-06-21 2019-06-20 Композиция, содержащая аналог соматостатина, для радиофармацевтического применения EA202190096A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18179052 2018-06-21
PCT/EP2019/066329 WO2019243489A1 (en) 2018-06-21 2019-06-20 Composition containing a somatostatin analogue for radiopharmaceutical use

Publications (1)

Publication Number Publication Date
EA202190096A1 true EA202190096A1 (ru) 2021-03-22

Family

ID=62748818

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190096A EA202190096A1 (ru) 2018-06-21 2019-06-20 Композиция, содержащая аналог соматостатина, для радиофармацевтического применения

Country Status (12)

Country Link
US (1) US11969484B2 (ru)
EP (1) EP3810209A1 (ru)
JP (2) JP7482792B2 (ru)
KR (1) KR20210024017A (ru)
CN (1) CN112312933A (ru)
AU (1) AU2019289886B2 (ru)
CA (1) CA3103190A1 (ru)
EA (1) EA202190096A1 (ru)
IL (1) IL279478A (ru)
SG (1) SG11202012378SA (ru)
TW (1) TW202015744A (ru)
WO (1) WO2019243489A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240051918A (ko) * 2021-06-29 2024-04-22 라이프 몰레큘러 이미징 리미티드 방사성금속 표지된 킬레이트-관능화된 표적화 접합체의 방사성약제 제조를 위한 신규 키트

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US8691761B2 (en) * 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
CN101631801B (zh) * 2006-10-16 2013-06-05 索尔克生物学研究院 受体(sstr2)-选择性生长抑素拮抗剂
EP3015462A1 (en) * 2014-10-29 2016-05-04 OctreoPharm Schiences GmbH Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals
EP3218015A2 (en) 2014-11-12 2017-09-20 Immunomedics, Inc. Methods and compositions for improved labeling of targeting peptides
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
WO2018065634A1 (en) * 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs

Also Published As

Publication number Publication date
EP3810209A1 (en) 2021-04-28
IL279478A (en) 2021-01-31
US11969484B2 (en) 2024-04-30
SG11202012378SA (en) 2021-01-28
JP2021527681A (ja) 2021-10-14
JP2024045148A (ja) 2024-04-02
WO2019243489A1 (en) 2019-12-26
AU2019289886B2 (en) 2024-10-17
US20230181771A1 (en) 2023-06-15
TW202015744A (zh) 2020-05-01
KR20210024017A (ko) 2021-03-04
AU2019289886A1 (en) 2021-01-21
CA3103190A1 (en) 2019-12-26
CN112312933A (zh) 2021-02-02
JP7482792B2 (ja) 2024-05-14

Similar Documents

Publication Publication Date Title
PE20180571A1 (es) Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
EA201990071A1 (ru) Композиция пептидной вакцины
EA201990298A1 (ru) Способы и композиции для лечения рака
MX2013013913A (es) Polipeptidos.
PA8798901A1 (es) Nuevos derivados de 6- aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet"
PH12018502465A1 (en) Mic-1 compounds and use thereof
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
BR112019008349A2 (pt) composição de peptídeos, e, utilização de uma composição.
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
EA201690159A1 (ru) Способы и композиции для лечения рака
EA200970132A1 (ru) Аналоги морфолинила и пирролидинила
PH12019550241A1 (en) Mic-1 compounds and uses thereof
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112018001980A2 (pt) compostos cíclicos úteis como moduladores de tnf alfa
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
EA202190888A1 (ru) Пептид для применения в косметике
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
EA202091007A1 (ru) Способ снижения времени восстановления высушенных распылением белковых составов
PH12021550122A1 (en) Solubilized apyrases, methods and use
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA202190096A1 (ru) Композиция, содержащая аналог соматостатина, для радиофармацевтического применения
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
ZA202102816B (en) High concentration protein formulation
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии